Reuters logo
BRIEF-Neurocrine and Bial reports exclusive North American licensing agreement for opicapone
February 9, 2017 / 9:13 PM / 8 months ago

BRIEF-Neurocrine and Bial reports exclusive North American licensing agreement for opicapone

Feb 10 (Reuters) - Neurocrine Biosciences Inc :

* Neurocrine and Bial announce exclusive North American licensing agreement for opicapone

* Neurocrine will be responsible for development and commercialization of opicapone in united states and canada

* Will make upfront payment of $30 million and will fund all development activities necessary for U.S. FDA approval

* Will pay Bial a percentage of net sales in exchange for manufacture and supply of opicapone drug product

* Neurocrine Biosciences - upon completion of technology transfer from Bial, neurocrine intends to meet with fda to discuss potential NDA submission

* Neurocrine Biosciences - Bial eligible to receive additional milestone payments of about $115 million from neurocrine for achievement of certain milestones Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below